Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases
Pathology - Research and Practice · 2023
DOI: 10.1016/j.prp.2023.154543 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2023. Verfasst von Giuseppe Broggi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Anatomic Pathology, University of Catania, 95123 Catania, Italy.…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
PReferentially expressed Antigen in Melanoma (PRAME) is a cancer testis antigen, first isolated in tumor-reactive T-cell clones from a metastatic melanoma patient. It has been widely studied in skin pathology as an immunohistochemical marker capable of distinguishing between benign nevi and malignant melanomas. PRAME has been found to be also expressed in non-melanocytic tumors, including lung, breast, kidney and ovarian cancer. However, less is known about the diagnostic and/or prognostic role of this protein in uveal melanoma (UM); few studies have reported that PRAME expression seems to give to UM patients an additional metastatic risk beyond the other already-known prognostic parameters. In the present retrospective study, we aimed to correlate PRAME immunoreactivity to other clinico-pathologic features and follow-up data on a large series of 85 cases (45 non-metastasizing and 40 metastasizing tumors) of primary UM. A statistically significant correlation was found between PRAME expression and higher metastatic risk and lower metastasis-free survival. We propose to include PRAME in the immunohistochemical panel of UM as an easily usable marker capable of predicting higher metastatic risk and stratifying patients' outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Anatomic Pathology, University of Catania, 95123 Catania, Italy. Electronic address: giuseppe.broggi@gmail.com.
- Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Anatomic Pathology, University of Catania, 95123 Catania, Italy.
- Department of Ophthalmology, University of Catania, 95123 Catania, Italy.
- Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
- Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Human Anatomy, University of Catania, 95123 Catania, Italy.
- Department of Medicine and Health Sciences "V. Tiberio", University of Molise, 86100 Campobasso, Italy.
Zitieren
APA
Broggi, G., Failla, M., Russo, A., Longo, A., Palicelli, A., Zanelli, M., Lombardo, C., Loreto, C., Merolla, F., Di Crescenzo, R. M., Ilardi, G., Varricchio, S., Staibano, S., & Caltabiano, R. (2023). Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2023.154543
Vancouver
Broggi G, Failla M, Russo A, Longo A, Palicelli A, Zanelli M, et al. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases. Pathology - Research and Practice. 2023. doi:10.1016/j.prp.2023.154543
BibTeX
@article{Broggi2023,
author = {Broggi, Giuseppe and Failla, Maria and Russo, Andrea and Longo, Antonio and Palicelli, Andrea and Zanelli, Magda and Lombardo, Claudia and Loreto, Carla and Merolla, Francesco and Di Crescenzo, Rosa Maria and Ilardi, Gennaro and Varricchio, Silvia and Staibano, Stefania and Caltabiano, Rosario},
title = {Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases},
journal = {Pathology - Research and Practice},
year = {2023},
doi = {10.1016/j.prp.2023.154543}
}
EUVIMED